anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention describes a novel antibacterial treatment on textile materials using polymeric core-shell particles dispersing in water. These particles are prepared from a surfactant-free emulsion polymerization according to the method of U.S. Pat. No. 6,573,313 and have average particle sizes in the range of 100 to 1000 nm in diameter. When applied to a textile article, the particles form a uniform coating, which prevents the growth of bacteria and microbes. The treatment does not affect the fabric mechanical properties, hand feeling and appearance. Antibacterial activity on cotton is maintained even after 50 times of home laundering.
There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. All ASD participants were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders 5th Edition's (DSM-5) diagnostic criteria (APA, 2013) and conﬁrmed by clinical consensus. ASD individuals were recruited from a community autism program and referred to children's health doctors and child psychiatrists. Exclusion criteria for all participants were neurological abnormalities, a history of epilepsy or seizures, head trauma and IQ \<75. The subjects did not participate in any intervention or drug programs during the experimental period.
The present invention relates to humanized anti-claudin-1antibodies and uses thereof. Hepatitis c virus infection is the leading cause of chronic liver disease and is also a major indicator of liver transplantation. The tight junction protein claudin-1(CLDN1) is an essential candidate for HCV and is a promising target for therapy. For clinical development, the present inventors have humanized rat anti-CLDN 1 antibody generated by genetic immunization, which prevents HCV infection and also cures chronically infected human liver chimeric mice. An important humanized anti-CLDN 1 antibody (H3L3) potently suppressed HCV pseudoparticle infection of Primary Human Hepatocytes (PHH) without detectable escape. H3L3 was effective in inhibiting infection by a variety of HCV genotype 3 strains and showed significant synergy with a direct acting antiviral Drug (DAA). The inventors also demonstrated that anti-CLDN 1H3L3 cured persistent HCV infection in human liver chimeric uPA-SCID mice in monotherapy. Thus, the present invention relates to humanized anti-claudin-1antibodies and uses thereof, particularly for the prevention and treatment of hepatitis c virus infection, virus-induced liver disease, hepatocellular carcinoma (HCC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
A double-blind, randomized, 12-week study was performed in patients with a clinical and/or genotypic diagnosis of HoFH. Data were analyzed from a subgroup of patients (n=36) receiving atorvastatin 40 mg at baseline. Increasing the dose of atorvastatin from 40 to 80 mg (n=12) produced a reduction of LDL-C of 2% from baseline on atorvastatin 40 mg. Coadministered ezetimibe and atorvastatin equivalent to ezetimibe and atorvastatin tablets (10/40 and 10/80 pooled, n=24), produced a reduction of LDL-C of 19% from baseline on atorvastatin 40 mg. In those patients coadministered ezetimibe and atorvastatin equivalent to ezetimibe and atorvastatin tablets (10/80, n=12), a reduction of LDL-C of 25% from baseline on atorvastatin 40 mg was produced.

After completing the 12-week study, eligible patients (n=35), who were receiving atorvastatin 40 mg at baseline, were assigned to coadministered ezetimibe and atorvastatin equivalent to ezetimibe and atorvastatin tablets 10/40 for up to an additional 24 months. Following at least 4 weeks of treatment, the atorvastatin dose could be doubled to a maximum dose of 80 mg.

At the end of the 24 months, ezetimibe and atorvastatin tablets (10/40 and 10/80 pooled) produced a reduction of LDL-C that was consistent with that seen in the 12-week study.
The present invention belongs to the technical field of Chinese patent medicines. The medicines for treating stomach ache, stomach heat and gastric hyperacidity has low medical therapeutic effects in the existing medical material market. Stomach impairment is mainly caused by damp heat due to foods and drinks for excessive consumption of acrid foods and excessive drinking. The gastric mucosa is damaged by extensive gastric acid to result in ulcer of the stomach and the duodenum, perforation, profuse bleeding or cancerization, etc. Thus, stomach fire is eliminated, and gastric acid is controlled within a normal range. The present invention is prepared from chicken's gizzard-membrane, pueravia flower, coptis, catechu, orange fruit, cicada slough, Indian trum etflower seed, dandelion, philippine violet herb, dried tangerine peel, felicitous plant glossy ganoderma, galanga galangal seed, etc. The present invention has the technical scheme that galanga galangal seed, which is always ignored in the medical field, is mainly used as a paradoxical assistant medicine to perform the obvious effect of mutual oppositeness and complementariness. The present invention is mainly used for treating stomachache, stomach distention, gastric hyperacidity, stomach impairment for alcoholic toxicity, stomach heat, duodenal ulcer and various kinds of gastritis with the symptoms and is used for cool drinkers. The present invention has the advantages of security, low cost, extensive medicine source, simple preparation process and easy control and is suitable for using by extensive patients.
Risk Summary

Based on its mechanism of action, ELAHERE can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (DM4) and affects actively dividing cells [see Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)]. Human immunoglobulin G (IgG) is known to cross the placental barrier; therefore, ELAHERE has the potential to be transmitted from the mother to the developing fetus. There are no available human data on ELAHERE use in pregnant women to inform a drug-associated risk. No reproductive or developmental animal toxicity studies were conducted with mirvetuximab soravtansine-gynx. Advise patients of the potential risk to a fetus. 

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data: No reproductive or developmental animal toxicity studies have been conducted with mirvetuximab soravtansine-gynx. The cytotoxic component of ELAHERE, DM4, disrupts microtubule function, is genotoxic, and can be toxic to actively dividing cells, suggesting it has the potential to cause embryotoxicity and teratogenicity.
This program recruits mothers in OB/GYN offices. Mothers are offered visits from a Navigator prenatally and postnatally (12-, 24-, and 36-months). During visits, the Navigator works with the mother to identify family needs, establishes connections between the family and community providers, and follows up one month later to confirm these referrals. Navigators assess and support family needs across 13 factors: caregiver health, infant health, healthcare plans, childcare plans, parent-child relationship, management of infant crying/behavior, household safety/material supports, family/community violence, history of parenting difficulties, parent well-being, substance use, parent emotional support, and other needs not related to first 12 factors. Navigation 2.0 is a revision of 1.0 in which adjustments to the protocol were made to improve guidance for Community Navigators and aid their assessments of family needs.
Sex differences in allergic inflammation have been reported, but the mechanisms underlying these differences remain unknown. Contributions of both sex hormones and sex-related genes to these mechanisms have been previously suggested in clinical and animal studies. Here, Four-Core Genotypes (FCG) mouse model was used to study the inflammatory response to house dust mite (HDM) challenge and identify differentially expressed genes (DEGs) and regulatory pathways in lung tissue. Briefly, adult mice (8-10 wk old) of the FCG (XXM, XXF, XYM, XYF) were challenged intranasally with 25 μg of HDM or vehicle (PBS-control group) 5 days/wk for 5 wk (n = 3/10 group). At 72 h after the last exposure, we analyzed the eosinophils and neutrophils in the bronchoalveolar lavage (BAL) of FCG mice. We extracted lung tissue and determined DEGs using Templated Oligo-Sequencing (TempO-Seq). DEG analysis was performed using the DESeq2 package and gene enrichment analysis was done using Ingenuity Pathway Analysis. A total of 2,863 DEGs were identified in the FCG. Results revealed increased eosinophilia and neutrophilia in the HDM-treated group with the most significantly expressed genes in XYF phenotype and a predominant effect of female hormones vs. chromosomes. Regardless of the sex hormones, mice with female chromosomes had more downregulated genes in the HDM group but this was reversed in the control group. Interestingly, genes associated with inflammatory responses were overrepresented in the XXM and XYF genotypes treated with HDM. Sex hormones and chromosomes contribute to inflammatory responses to HDM challenge, with female hormones exerting a predominant effect mediated by inflammatory DEGs.NEW & NOTEWORTHY Gene expression profiling helps to provide deep insight into the global view of disease-related mechanisms and responses to therapy. Using the Four-Core Genotype mouse model, our findings revealed the influence of sex hormones and sex chromosomes in the gene expression of lungs exposed to an aeroallergen (House Dust Mite) and identified sex-specific pathways to better understand sex disparities associated with allergic airway inflammation.
Oxycodone HCl Controlled-Release Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. 

Oxycodone HCl Controlled-Release Tablets are NOT intended for use as a prn analgesic. 

Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for Health Care Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. 

Oxycodone HCl Controlled-Release Tablets are not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. Oxycodone HCl Controlled-Release Tablets are only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)
FIELD: medicine. ^ SUBSTANCE: there is disclosed pharmaceutical product as prepared solution. The pharmaceutical product comprises a reservoir filled with dissolved zoledronic acid or its pharmaceutically acceptable salt. At least the internal surface of said reservoir contains plastic material that is polyolefin. The product is exposed to thermal sterilisation, preferentially to moist thermal sterilisation. Besides the product can contain a buffer component, preferentially the buffer organic base. Additionally, the product can contain an isotonic component, preferentially mannitol. The invention provides product sterilisation at high temperature 121C during 150 minutes without visible deformations and damages of sealed integral reservoir, as well as decomposition of pharmaceutical substance. ^ EFFECT: thermal stability allows for multiple sterilisation cycle that leads to sterility assurance level at least 10-12. ^ 38 cl, 19 ex
The invention provides a lyophilized tablet prepared from a glyburide composition and a preparation method thereof and belongs to the technical of medicines and medicine production. The lyophilized tablet is prepared from glyburide, starch and sucrose, wherein the starch and the sucrose serve as adjuvants. By heating the common corn starch, the binding and disintegrating effects of the starch in the lyophilized tablet can be improved, and the formability of the lyophilized tablet can be improved. The adjuvants for preparing the lyophilized tablet only comprise the starch and the sucrose. The lyophilized tablet is prepared by decreasing temperature twice and increasing temperature twice, and the twice temperature decrease and twice temperature increase can ensure that the lyophilized tablet can be well formed, the dissolution rate of the lyophilized tablet can be increased and the bioavailability of the lyophilized tablet can be improved. The lyophilized tablet overcomes the defects of the ordinary tablet prepared from glyburide, is prepared by adopting a few kinds of and a small amount of adjuvants compared with the tablet prepared from glyburide, has high dissolution rate and high bioavailability, has a good clinical treatment effect and can be used for clinical treatment safely.
Participants in this group will receive five hours of face-to-face empowerment training. After the training, the experimental group will be monitored remotely by the researcher nurse via tele-nursing interventions for 12 weeks. Participants will be given a pulse oximeter, symptom diary, action plan, oxygen saturation-pulse monitoring chart. Participants will be asked to measure their oxygen saturation and pulse once a day for 12 weeks and record it on the chart. Participants will also be asked to record their complaints in their symptom diary. Participants will be called by the researcher every two weeks (on Thursdays) and informative and reminding text messages prepared specifically for the disease will be sent to the participants three times a week for 12 weeks. Participants will be able to reach the researchers by phone whenever they need.
Porous polymers having a plurality of openings or chambers that are highly convoluted, with each chamber being defined by multiple, thin, flat partitions are produced by a new gel enhanced phase separation technique. In a preferred embodiment, a second solvent is added to a polymer solution, the second solvent causing the solution to gel. The gel can then be shaped as needed. Subsequent solvent extraction leaves the porous polymeric body of defined shape. The porous polymers have utility as medical prostheses, the porosity permitting ingrowth of neighboring tissue. The present technique also enhances shape-making capability, for example, of bifurcated vascular grafts, which feature a common entrance region but two or more exit regions.
In the current study the plan is to recruit 600 patients who have been referred to the echocardiogram laboratory for routine clinically indicated echocardiography, or to the cardiac catheterization laboratory for routine clinically indicated catheterization procedures. Individuals with normal heart structure and sounds, isolated aortic stenosis (of varying severity), and isolated mitral regurgitation (of varying severity) will be included, while excluding individuals who have multiple valve involvements or combined valve pathologies. Each patient will have baseline testing using the ©CompuSteth device, which will be used to auscultate and record each patient's heart sounds at the bedside prior to the index echocardiogram or cardiac catheterization procedure. This process will take less than 10 minutes and is outlined below. Patients will then proceed with their clinically indicated echocardiograms or cardiac catheterization procedures.

Amongst the first 200 study participants, the results of the echocardiograms and invasive cardiac catheterization procedures will be used to train the ©VoqX device to identify normal heart and to screen and grade for various cardiac structural pathologies, aortic stenosis, and mitral regurgitation, diagnosed by gold-standard testing. Subsequently, after the ©VoqX device has been trained how to characterize and identify sounds that correspond to various structural cardiac pathologies, the next step is to prospectively 'test' how well the ©VoqX device is able to screen normal heart from cardiac pathologies, such as aortic stenosis, and mitral regurgitation, and identify the severity of the valve disorder in the subsequent 200 participants of the study. This will be done by comparing the results obtained from auscultation with the ©VoqX device against the results obtained from gold-standard testing with echocardiography or invasive cardiac catheterization.
This is a two-part open-label clinical trial of blueberry powder administered to patients with stage IV NSCLC in combination with docetaxel as a second line treatment. Patients will initially be enrolled in part 1 of the study, which is the feasibility/toxicity evaluation section of the study. Once the part I enrollment is completed, the patients will be enrolled in part 2 of the study.
BACKGROUND: To date, an effective means to preoperatively predict the malignant transformation of sinonasal inverted papilloma (SIP) remains lacking due to similarities in clinical appearance. This study aimed to retrospectively evaluate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters and microvessel structure in tumors with histologically confirmed SIP and inverted papilloma-associated squamous cell carcinoma (IP-SCC), as well as correlate DCE-MRI findings with angiogenesis biomarkers.
METHODS: Absolute quantitative DCE-MRI parameters (Ktrans, Kep, Ve) based on the Tofts model and model-free semi-quantitative indices (Tpeak, WR, MaxSlope) of SIP (n = 22) and IP-SCC (n = 20) were investigated. Regions of interest (ROIs) were oriented according to the tumor subsites in the surgical records. Micro-vessel density (MVD) counts and tight junction protein (claudin-5) expression were evaluated in tumor specimens obtained during surgery. Differences in the above data were compared between the two groups. Correlations between DCE-MRI parameters and angiogenic biomarkers were analyzed.
RESULTS: Compared with SIP specimens, IP-SCC specimens were characterized by a significantly higher MVD and a leakier microvessel barrier. The values of Tpeak and Ve were significantly higher for SIP than those for IP-SCC, whereas WR, MaxSlope, and Kep were significantly lower, indicating early enhancement and a faster dispersion model in IP-SCC. MVD was positively correlated with WR and Kep and negatively correlated with Tpeak. Tpeak was slightly positively correlated to claudin-5 expression.
CONCLUSION: DCE-MRI can serve as a noninvasive biomarker of angiogenesis in the malignant transformation from SIP to IP-SCC. DCE-MRI may assist in the differentiation of malignancies and treatment selection.
Paclitaxel IV given over 1 hour at 80 mg/m2 days 1, 8 and 15 of a 28-day cycle. PLUS ganetespib IV at MTD/MED from Phase I on days 1, 8 and 15 of a 28-day cycle.
The invention provides food or a healthcare product or a medicine composition containing barbary wolfberry fruits and reducing blood glucose. The food or the healthcare product or the medicine composition comprises, by weight, 1-10 parts of barbary wolfberry fruits and 10-20 parts of malus hupehensis leaves. The barbary wolfberry fruits are obtained after fresh wolfberry fruits are punched through a puncher and dried. It is found that after the barbary wolfberry fruits and the malus hupehensis leaves are combined for use, the synergistic interaction effect is achieved, hypoglycemic activity is improved, and the effect is superior to that achieved through independent use of the barbary wolfberry fruits and the malus hupehensis leaves through research. It is further found that after the barbary wolfberry fruits and the malus hupehensis leaves are combined at the specific ratio of 5:15, the blood glucose reducing effect is better, and the effect is superior to that achieved through combination of barbary wolfberry fruits and malus hupehensis leaves at other ratios of 1:10 and 10:10 in experiments. Based on the research, the novel composition reducing blood glucose is provided for providing a new choice for clinical medication and healthcare treatment.
A repeated measures clinical study design will be carried out with 30 Veterans. 'Pre-baseline' seated interface pressures will be assessed with study participants sitting on their own cushions and pelvic region skin checks carried out by the study Research Nurse. All participants will then receive customized modular cushions. Participants will be randomly assigned to Group A or Group B using a modified randomization scheme. Group A participants will first use a gel ball fitted cushion for 2 weeks during all daily living activities while seated in their wheelchair followed by use of a SquishINS fitted cushion for 2 weeks. Group B will first use the SquishINS fitted cushion then a gel ball fitted cushion. Seated interface pressure distribution will be obtained at the beginning and end of each test period. A dual temperature and humidity sensor placed in the cushion will enable continuous monitoring of microenvironmental status during use. The study Research Nurse will repeat the pelvic region skin check and participants will complete a questionnaire based on the QUEST 2.0 user satisfaction instrument. All responses will be documented as part of the QS/DC program.
The invention relates to a traditional Chinese medicine preparation for treating thrombocytopenia and a preparation method thereof. The traditional Chinese medicine preparation consists of pig nail, rehmannia root, red paeony root and tree peony bark which are formulated according to the theory of the traditional Chinese medical science, strictly screened, respectively prepared and combined into the traditional Chinese medicine preparation by the modern advanced preparation technique. The traditional Chinese medicine preparation has the effects of clearing heat and nourishing Yin and cooling blood and invigorating the circulation of blood. The invention is used for treating primary thrombocytopenic purpura blood-head Yin impairment blood stasis, symptomatic skin purpura, gingival hemorrhage, epistaxis, menorrhagia, thirst, feverish dysphoria, night sweat and the like. The invention also can be used for patients with the heat-toxin Yin impairment blood stasis of thrombocytopenia causedby tumor chemotherapy in the traditional Chinese medical science. The preparation has the advantages of reasonable formula, assured curative effect, safety, reliability, easy medicine obtaining and cheapness, and is worth popularizing and applying in clinic.